What the NICE guidelines for Mounjaro mean for you

What the NICE appraisal committee actually concluded

NICE's committee reviewed tirzepatide in the context of a crowded treatment landscape and concluded the evidence was strong enough to recommend it for NHS use within specific criteria. The foundation of that decision was SURMOUNT-1, a 72-week randomised trial involving 2,539 adults with obesity. At the 15mg dose, participants lost an average of around 20–21% of their body weight, a figure the committee described as clinically meaningful and superior to the comparators available at the time. The recommendations chapter of TA1026 sets out the full eligibility criteria, the monitoring expectations, and the condition under which treatment should be reviewed: if someone hasn't lost at least 5% of their starting weight after six months at the highest tolerated dose, continuation is assessed.

The committee also noted indirect comparisons with semaglutide (Wegovy), and those comparisons favoured tirzepatide. That finding was later reinforced by SURMOUNT-5, a 72-week head-to-head trial published in the New England Journal of Medicine in 2025, which showed tirzepatide producing greater average weight loss than semaglutide 2.4mg in adults with obesity and without diabetes. Results from clinical trials aren't universal (individual responses vary) but the evidence base behind TA1026 is substantial.

One practical point the appraisal touches on: tirzepatide carries a Black Triangle (▼) designation, meaning the MHRA is collecting additional safety data. That doesn't reflect a specific concern; it's standard for newer medicines and reflects ongoing monitoring rather than a warning.

Who the NICE BMI thresholds apply to, and how the NHS rollout is structured

The NICE criteria aren't delivered in one wave. NHS England is phasing access over several years, and the cohort definitions matter. From June 2025, tirzepatide became available on the NHS for adults with a BMI of 40 or above who also have four or more of five qualifying conditions: high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, and type 2 diabetes. A second cohort (BMI 35–39.9 with four or more of those conditions) became eligible from June 2026. Further cohorts are planned into 2027. At each stage, patients need to engage with wraparound diet and activity support; meeting the numbers isn't enough on its own.

For some ethnic groups, the thresholds are adjusted downward by 2.5 kg/m², in line with evidence that metabolic risk accumulates at lower BMI values. A South Asian adult, for example, would qualify at BMI 32.5 rather than 35. The NHS England weight management injections page sets out the current phased criteria clearly and is updated as new cohorts open.

If you're wondering whether you'd qualify under the NHS criteria and your GP surgery is participating (not all are yet, since GP prescribing under the new contract is optional) our FAQs page covers common questions about NHS versus private routes.

Private prescribing: where the licensed SmPC criteria differ from TA1026

NICE guidelines govern NHS commissioning. Private prescribers follow the licensed prescribing criteria set out in the Mounjaro SmPC, and those allow a lower entry point: adults with a BMI of 27 or above qualify if they have at least one weight-related condition. The conditions that count include prediabetes, type 2 diabetes, hypertension, high cholesterol, and obstructive sleep apnoea, among others.

That's a meaningful difference. Someone with a BMI of 30 and treated high blood pressure meets the private licensed criteria but does not yet meet the NHS NICE threshold. For people in that position (or those who'd rather not wait on a GP list) a private weight-loss treatment reviewed by a GPhC-registered prescriber is a lawful and regulated alternative. It's also worth understanding what private pricing tends to include (and what it sometimes doesn't), which the Mounjaro price comparison page covers in detail.

BMI alone doesn't determine clinical suitability in either route. A prescriber considers the full picture: other medicines, relevant history, contraindications. The NICE document and the SmPC are both starting frameworks; the clinical assessment is where the detail lives. Questions about age eligibility specifically (there are some nuances worth knowing) are covered on the Mounjaro age eligibility page.

One question the guidelines don't answer: what happens if you don't qualify yet

NICE TA1026 doesn't address people who fall just outside the NHS thresholds, that's outside its remit. And for many people, that gap is genuinely frustrating. You might have a BMI of 32, a diagnosis of sleep apnoea, and a strong clinical case, yet not hit the current NHS numbers. You're not doing anything wrong; the phased rollout reflects NHS capacity, not the strength of your case.

Private treatment, where clinically appropriate, fills that gap. The process through a regulated UK pharmacy is straightforward: a consultation reviewed by a prescriber on the same day, identity and weight verified, and treatment dispatched if approved, no referral required, no waiting list. If you're unsure whether the licensed criteria apply to you, the starting point is a conversation with a clinician, not a self-assessment against a table of numbers. You can learn how an online Mounjaro consultation works before committing to anything. Many people also ask about nutrition while on treatment, and if that applies to you, our guide to choosing the best collagen supplement to take alongside Mounjaro is worth reading. And if you'd like to understand the broader context of how tirzepatide compares with other treatments coming down the pipeline, the retatrutide versus Mounjaro comparison is worth a read.

If you think you might be eligible and want a prescriber to assess your situation properly, speak to our prescribers, consultations are free, there's no obligation, and the clinical review happens the same day. If you're planning ahead on cost, you can also find out whether there are any current discount codes available for Mounjaro before you complete your order.